TA-650
Phase 3Small molecule
Tanabe Pharma CorporationTA-650 is one of 92 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.
3
Indications
7
Total Trials
0
Active Trials
91
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Rituxan
RochePreclinical
TA-650
Tanabe Pharma CorporationPhase 3
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Ilaris
NovartisPreclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Zelhou
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Rituxan
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Behcet's Disease1 trial
Rheumatoid Arthritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TA-650. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company